IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v47y2024i2d10.1007_s40264-023-01379-0.html
   My bibliography  Save this article

A Descriptive Analysis of Adverse Event Reports from the Quebec Cannabis Registry

Author

Listed:
  • Yasmina Hachem

    (McGill University Health Center
    Harvard Medical School)

  • Yola Moride

    (Rutgers, The State University of New Jersey
    YolaRX Consultants)

  • Anne-Marie Castilloux

    (YolaRX Consultants)

  • Genaro Castillon

    (YolaRX Consultants)

  • Maja Kalaba

    (Canopy Growth Corporation)

  • Andrée Néron

    (Bureau d’évaluation médicale (Consultant on request in medical cannabis-related pharmacological assessments and needs for injured workers))

  • Rihab Gamaoun

    (Research Institute of the McGill University Health Centre)

  • Marc O. Martel

    (McGill University)

  • Pierre Beaulieu

    (Faculté de médecine de l’Université de Montréal)

  • Mark Ware

    (McGill University Health Center)

  • Antonio Vigano

    (McGill University Health Center
    McGill University Health Center)

Abstract

Introduction Published data on the safety of natural medical cannabis (MC) when used in the real-world clinical practice setting are lacking. This study aimed to describe adverse events (AEs) reported across three years following MC initiation. Methods The Quebec Cannabis Registry (QCR) was a prospective registry of adults enrolled through participating physicians when they initiated MC between May 2015 and October 2018. Follow-up ended at MC discontinuation, loss to follow-up, three years, or end of data collection (May 2019). Data were collected at baseline and at follow-up visits every three months for the first two years, then once in the third year. Physicians filled adverse event (AE) reports, which were coded using MedDRA® preferred terms (PTs), and descriptive analyses were conducted. Results A total of 2991 patients were enrolled (mean age 50.9 years, 50.2% females). During follow-up, 108 patients (3.6%) experienced moderate or severe AEs, yielding 111 AE reports (three patients had two reports) and 214 AEs (average 1.9 AEs per report). Mild AEs were recorded as a reason for MC discontinuation for nine patients, but no AE reports were available. The most common PTs for ingested MC (62 reports) were dizziness (12.9%), nausea (11.3%), somnolence (9.7%), and vomiting (8.1%), and for inhaled MC (23 reports), headache (13.0%) was the most common. The most frequent PTs associated with tetrahydrocannabinol (THC)-dominant MC (25 reports) were dizziness and somnolence (12.0% each); for cannabidiol (CBD)-dominant MC (20 reports), vomiting (20.0%) was most common; and dizziness (17.2%), nausea (13.8%), somnolence (10.3%), and headache (8.6%) were the most frequent for balanced MC (58 reports). Conclusion No new safety concerns were identified relative to the published literature, although notable differences in AE profile between modes of administration and cannabinoid content ratios should be considered by health professionals. Further work identifying and managing risk factors for AEs is warranted to maintain a favorable benefit-risk balance for MC.

Suggested Citation

  • Yasmina Hachem & Yola Moride & Anne-Marie Castilloux & Genaro Castillon & Maja Kalaba & Andrée Néron & Rihab Gamaoun & Marc O. Martel & Pierre Beaulieu & Mark Ware & Antonio Vigano, 2024. "A Descriptive Analysis of Adverse Event Reports from the Quebec Cannabis Registry," Drug Safety, Springer, vol. 47(2), pages 161-171, February.
  • Handle: RePEc:spr:drugsa:v:47:y:2024:i:2:d:10.1007_s40264-023-01379-0
    DOI: 10.1007/s40264-023-01379-0
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-023-01379-0
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40264-023-01379-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:47:y:2024:i:2:d:10.1007_s40264-023-01379-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.